IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION
100 Army Post Road – Des Moines, IA 50315 □ (515) 974-3131 □ Fax 1-866-626-0216

Brett Faine, Pharm.D.
Melissa Klotz, Pharm.D.
Jason Kruse, D.O
Mark Graber, M.D., FACEP, MSHCE
Kellen Ludvigson, Pharm.D.
Susan Parker, R.Ph., Pharm.D.
Laurie Anderson, R.Ph., Pharm.D.
Daniel Gillette, M.D.
Jason Wilbur, M. D.
Sandy Pranger, R.Ph.

Professional Staff: Pam Smith, R.Ph.
DUR Project Coordinator

October 6, 2017

Susan L. Parker, R.Ph, Pharm.D.
Pharmacy Director
Iowa Medicaid Enterprise
100 Army Post Road
Des Moines, Iowa 50315

Dear Susan:

The Iowa Medicaid Drug Utilization Review (DUR) Commission met on Wednesday, October 4, 2017. At this meeting, the DUR Commission members discussed the proposed prior authorization (PA) criteria for Dupilumab (Dupixent) and a ProDUR age edit on tramadol. The following recommendations have been made by the DUR Commission:

The DUR Commission reviewed comments that were received from the medical/pharmacy associations in response to an August 8, 2017 letter that was sent to them detailing the proposed criteria for Dupilumab (Dupixent) and the ProDUR age edit on tramadol.

Dupilumab (Dupixent)

Newly Proposed Clinical Prior Authorization Criteria

Prior authorization is required for Dupixent (dupilumab). Payment will be considered for patients when the following criteria are met:

1. Patient has a diagnosis of moderate-to-severe atopic dermatitis; and
2. Patient is within the FDA labeled age; and
3. Is prescribed by or in consultation with a dermatologist; and
4. Patient has failed to respond to good skin care and regular use of emollients; and
5. Patient has documentation of an adequate trial and therapy failure with one preferred medium to high potency topical corticosteroid for a minimum of 2 consecutive weeks; and
6. Patient has documentation of a previous trial and therapy failure with a topical immunomodulator for a minimum of 4 weeks; and
7. Patient has documentation of a previous trial and therapy failure with cyclosporine or azathioprine; and

8. Patient will continue with skin care regimen and regular use of emollients; and
9. Dose does not exceed an initial one-time dose of 600mg and maintenance dose of 300mg thereafter given every other week.

If criteria for coverage are met, initial authorizations will be given for 16 weeks to assess the response to treatment. Request for continuation of therapy will require documentation of a positive response to therapy.
The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Due to the recent changes to the label of tramadol containing medications, the DUR Commission recommends implementing an age edit on all tramadol containing medications to restrict its use in members under 18 years of age and not allow the 72-hour emergency override in this population.

Thank you in advance for the Department's consideration of accepting the DUR Commission's recommendations for clinical prior authorization criteria for Dupilumab (Dupixent) and the ProDUR age edit on tramadol.

Sincerely,

Pamela Smith, R.Ph.
Drug Utilization Review Project Coordinator
Iowa Medicaid Enterprise

Cc: Erin Halverson, R.Ph, IME
Gina Tiernan, R.Ph, IME